TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-02-24
Target enrollment:
Participant gender:
Summary
This phase I trial studies the best dose and side effects of TAK-659 and paclitaxel in
treating patients with advanced solid tumors. TAK-659 may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving TAK-659 and
paclitaxel may work better in treating patients with advanced solid tumors.